Format

Send to

Choose Destination
Clin Pharmacol Ther. 2017 Mar;101(3):341-358. doi: 10.1002/cpt.602.

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

Author information

1
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
2
UMR Inserm U1027 and Université de Toulouse III Paul Sabatier, Toulouse, France.
3
Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy.
4
Royal Dutch Pharmacists Association (KNMP), The Hague, The Netherlands.
5
Department of Clinical Pharmacy, Granada University Hospital, Institute for Biomedical Research, Granada, Spain.
6
Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands.
7
Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Slovenia.
8
Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden.
9
Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
10
Center for Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
11
The Golden Helix Foundation, London, United Kingdom.
12
University of Patras, School of Health Sciences, Department of Pharmacy, University Campus, Rion, Patras, Greece.
13
Department of Molecular and Clinical Pharmacology, Royal Liverpool University Hospital and University of Liverpool, Liverpool, United Kingdom.
14
Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria.
15
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany.
16
Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany.
17
Department of Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany.
18
Bio.logis Center for Human Genetics, Frankfurt am Main, Germany.
19
Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany.
20
Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.

Abstract

Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several implementation studies and programs have been initiated over recent years. This article presents an overview of these studies and identifies current research gaps. Importantly, one such gap is the undetermined collective clinical utility of implementing a panel of PGx-markers into routine care, because the evidence base is currently limited to specific, individual drug-gene pairs. The Ubiquitous Pharmacogenomics (U-PGx) Consortium, which has been funded by the European Commission's Horizon-2020 program, aims to address this unmet need. In a prospective, block-randomized, controlled clinical study (PREemptive Pharmacogenomic testing for prevention of Adverse drug REactions [PREPARE]), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which guidelines are available, will be implemented across healthcare institutions in seven European countries. The impact on patient outcomes and cost-effectiveness will be investigated. The program is unique in its multicenter, multigene, multidrug, multi-ethnic, and multihealthcare system approach.

PMID:
28027596
DOI:
10.1002/cpt.602
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center